For the year ending 2025-12-31, QTTB had -$29,668K decrease in cash & cash equivalents over the period. -$33,543K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income (loss) | 29,821 |
| Non-cash revenue from settlement of customer refund liability | 53,737 |
| Amortization of debt discount and issuance costs | 180 |
| Amortization of premium on short-term investments | 0 |
| Depreciation expense | 391 |
| Stock-based compensation expense | 5,255 |
| Non-cashlease expense | 622 |
| Loss from equity method investment | 0 |
| Loss on impairment of equity investment | 74 |
| Change in fair value of cvr liability | 374 |
| Change in fair value of convertible notes | 0 |
| Gain on sale of asset | 11,737 |
| Prepaid expenses and other current assets | -1,896 |
| Other noncurrent assets | -116 |
| Accounts payable | -2,110 |
| Operating lease liability | -612 |
| Accrued expenses and other current liabilities | -3,328 |
| Net cash used in operating activities | -33,543 |
| Purchases of property and equipment | 0 |
| Proceeds from sale of asset | 7,000 |
| Maturities of short-term investments | 0 |
| Net cash provided by investing activities | 7,000 |
| Proceeds from borrowings under loan and security agreement | 0 |
| Proceeds from issuance of common stock in pre-closing financing | 0 |
| Cash acquired in connection with reverse recapitalization | 0 |
| Payment of reverse recapitalization transaction costs | 0 |
| Principal payments on venture debt | -3,125 |
| Proceeds from exercise of common stock options | 0 |
| Net cash provided by (used in) financing activities | -3,125 |
| Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents | -29,668 |
| Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period | 78,612 |
| Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period | 48,944 |
Q32 Bio Inc. (QTTB)
Q32 Bio Inc. (QTTB)